GWS
RVNC

Glassman Wealth Services’s Revance Therapeutics, Inc. RVNC Stock Holding History

Glassman Wealth Services’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-26
Closed – – 1422
2019
Q2 		$0 Buy
+26
New +$328 ﹤0.01% 1417

Other funds holding RVNC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Glassman Wealth Services's RVNC Position: Q3 2019 in Review

Glassman Wealth Services sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2019, closing a stake of 26 shares.

Glassman Wealth Services first reported a position in RVNC in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 109 funds tracked by Wall St. Rank hold RVNC as of Q3 2019.

  • Glassman Wealth Services reported no remaining Revance Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Glassman Wealth Services sold 26 Revance Therapeutics, Inc. shares in Q3 2019.
  • Glassman Wealth Services first reported a position in Revance Therapeutics, Inc. in Q2 2019 and held it in 1 quarter.
  • Glassman Wealth Services's Revance Therapeutics, Inc. position peaked at $0 in Q2 2019.
  • 109 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2019.

Based on Glassman Wealth Services's 13F filing for Q3 2019, filed 1 Nov 2019.